Regulatory Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug BioSpaceThe FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns.RegulatoryRare DiseaseRead full story pharminent March 30, 2026 (Last updated: March 30, 2026) BioSpace The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns. RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I PipelineNext: Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
